Xiaolong Xu; Jie Ying; Taiping Tian; Tengwen Liu; Chunhua Chi; Zhizhong Gong; Jingpeng Gao; Meiping Qian; Wei Tan; Ran Cao; Shuixian Lv; Zhougui Ling; Shuo Wang; Bo Li; Qingquan Liu

doi:10.1016/j.eng.2024.03.013

PDF(983 KB)

工程（英文） ›› 2024, Vol. 40 ›› Issue (9) : 61-69. DOI: 10.1016/j.eng.2024.03.013

研究论文

Article

Xiaolong Xu ^a^,^b^,^c ,
Jie Ying ^d ,
Taiping Tian ^e ,
Tengwen Liu ^f ,
Chunhua Chi ^g ,
Zhizhong Gong ^a ,
Jingpeng Gao ^h ,
Meiping Qian ⁱ ,
Wei Tan ,
Ran Cao ,
Shuixian Lv ,
Zhougui Ling ,
Shuo Wang ^a^,^* ,
Bo Li ^a^,^b^,^* ,
Qingquan Liu ^a^,^b^,^c^,^*

作者信息 +

Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Long Coronavirus Disease (COVID) Cough: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study

Xiaolong Xu ^a^,^b^,^c^,^# ,
Jie Ying ^d^,^# ,
Taiping Tian ^e^,^# ,
Tengwen Liu ^f^,^# ,
Chunhua Chi ^g ,
Zhizhong Gong ^a ,
Jingpeng Gao ^h ,
Meiping Qian ⁱ ,
Wei Tan ,
Ran Cao ,
Shuixian Lv ,
Zhougui Ling ,
Shuo Wang ^a^,^* ,
Bo Li ^a^,^b^,^* ,
Qingquan Liu ^a^,^b^,^c^,^*

Author information +

History +

Abstract

Lianhua Qingke tablets, a patented traditional Chinese medicine that has validated clinical efficacy for treating cough caused by severe acute respiratory syndrome coronavirus 2 infection, lack rigorous evidence-based research evaluating their effect on long coronavirus disease (COVID) cough. A randomized, double-blind, placebo-controlled, multicenter clinical study was conducted among patients with long COVID cough from 19 hospitals and 23 community health centers in China. Patients were randomized 1:1 to receive either Lianhua Qingke tablets or placebo orally for 14 days (four tablets, 1.84 g, three times a day). The primary endpoint indicator was the disappearance of cough, with the remission of cough also considered. Among 482 randomized patients, 480 (full analysis set 480; per-protocol set 470; safety set 480) were included in the primary analysis. According to the full analysis, the time until cough disappearance was significantly shorter in the trial group than in the control group, with a significant increase in the 14-day cough disappearance rate. Accordingly, the time to cough remission was significantly shorter in the trial group than in the control group. The change in the total symptom score was significantly greater in the trial group than in the control group on days 7 and 14, consistent with the results indicated by the visual analog scale (VAS) and cough evaluation test (CET) scores. No serious adverse events were recorded during the study. Lianhua Qingke tablets significantly improved the clinical symptoms of patients with long COVID cough.

Keywords

Long coronavirus disease (COVID) cough / Traditional Chinese medicine / Clinical trial / Efficacy / Safety

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用

Xiaolong Xu, Jie Ying, Taiping Tian. . Engineering. 2024, 40(9): 61-69 https://doi.org/10.1016/j.eng.2024.03.013

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序

[1]	Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et al. Effectiveness of public health measures in reducing the incidence of COVID-19, SARS-CoV-2 transmission, and COVID-19 mortality: systematic review and meta-analysis. BMJ 2021; 375:e068302.
[2]	Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID-mechanisms, risk factors, and management. BMJ 2021; 374:n1648.
[3]	Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect 2022; 28 (5):657-66.
[4]	Fernández-De-Las-Peñas C, Guijarro C, Plaza-Canteli S, Hernández-Barrera V, Torres-Macho J. Prevalence of post-COVID-19 cough one year after SARS-CoV-2 infection: a multicenter study. Lung 2021; 199(3):249-53.
[5]	Fang X, Ming C, Cen Y, Lin H, Zhan K, Yang S, et al. Post-sequelae one year after hospital discharge among older COVID-19 patients: a multi-center prospective cohort study. J Infect 2022; 84(2):179-86.
[6]	Sarkar A, Omar S, Alshareef A, Fanous K, Sarker S, Alroobi H, et al. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: a systematic review. Hum Vaccin Immunother 2023; 19 (1):2212568.
[7]	Zhang L, Wu L, Xu X, Yuan Y, Jiang R, Yan X, et al. Efficacy and safety of Lianhua Qingke tablets in the treatment of mild and common-type COVID-19: a randomized, controlled, multicenter clinical study. Evid Based Complement Alternat Med 2022; 2022:8733598.
[8]	DeWitt ME, Tjaden AH, Herrington D, Schieffelin J, Gibbs M, Weintraub WS, et al. COVID-19 symptoms by variant period in the North Carolina COVID-19 community research partnership, North Carolina, USA. Emerg Infect Dis 2023; 29(1):207-11.
[9]	Sepiashvili R, Chikhladze M, Slavyanskaya T, Gamkredlidze S, Khachapuridze D. Role of antihistamines in the management of COVID-19 infection. Allergy Eur J Allergy Clin Immunol 2021; 76:492.
[10]	Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380 (9853):1583-9.
[11]	Hussein AARM, Ibrahim M, Makhlouf HA, Makhlouf NA, Abd-Elaal HK, Kholief KMS, et al. Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study. Egypt J Bronchol 2022; 16(1):52.
[12]	Kum E, Patel M, Diab N, Wahab M, Zeraatkar D, Chu DK, et al. Efficacy and tolerability of gefapixant for treatment of refractory or unexplained chronic cough: a systematic review and dose-response meta-analysis. JAMA 2023; 330 (14):1359-69.
[13]	Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallelgroup, phase 2b trial. Lancet Respir Med 2020; 8(8):775-85.
[14]	Smith J, Allman D, Badri H, Miller R, Morris J, Satia I, et al. The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1). Chest 2020; 157:111-8.
[15]	Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig 2020; 58(3):155-68.
[16]	Singh SJ, Baldwin MM, Daynes E, Evans RA, Greening NJ, Jenkins RG, et al. Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation. Lancet Respir Med 2023; 11 (8):709-25.
[17]	Ye L, Fan S, Zhao P, Wu C, Liu M, Hu S, et al. Potential herb-drug interactions between anti-COVID-19 drugs and traditional Chinese medicine. Acta Pharm Sin B 2023; 13(9):3598-637.
[18]	Peng W, Qi H, Zhu W, Tong L, Rouzi A, Wu Y, et al. Lianhua Qingke ameliorates lipopolysaccharide-induced lung injury by inhibiting neutrophil extracellular traps formation and pyroptosis. Pulm Circ 2023; 13 (4):e12295.
[19]	Deng L, Xia W, Liu X, Xie W, Zou X, Jiang D. Protective effect and mechanism of Lianhua Qingke tablets on acute bronchitis in rats. Central South Pharm 2020; 18:919-23.
[20]	Huang XF, Cheng WB, Jiang Y, Liu Q, Liu XH, Xu WF, et al. A network pharmacology-based strategy for predicting anti-inflammatory targets of Ephedra in treating asthma. Int Immunopharmacol 2020; 83:106423.
[21]	Kim W, Lee W, Huh E, Choi E, Jang YP, Kim YK, et al. Ephedra sinica Stapf and gypsum attenuates heat-induced hypothalamic inflammation in mice. Toxins 2019; 12(1):16.
[22]	Yi Y, Li W, Liu K, Xue H, Yu R, Zhang M, et al. Licorice-saponin A3 is a broadspectrum inhibitor for COVID-19 by targeting viral spike and antiinflammation. J Pharm Anal 2023; 14(1):115-27.
[23]	Mei J, Zhou Y, Yang X, Zhang F, Liu X, Yu B. Active components in Ephedra sinica Stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: potent COVID-19 therapeutic agents. J Ethnopharmacol 2021; 278:114303.
[24]	Yeh YC, Doan LH, Huang ZY, Chu LW, Shi TH, Lee YR, et al. Honeysuckle (Lonicera japonica) and huangqi (Astragalus membranaceus) suppress SARSCoV- 2 entry and COVID-19 related cytokine storm in vitro. Front Pharmacol 2021; 12:765553.
[25]	Kim M, Park KH, Kim YB. Identifying active compounds and targets of Fritillariae thunbergii against influenza-associated inflammation by network pharmacology analysis and molecular docking. Molecules 2020; 25(17):3853.